New drug cocktail proves superior for early breast Ca
Adding the anthracycline epirubicin to cyclophosphamide, methotrexate, and fluorouracil (CMF) is superior to CMF alone as adjuvant therapy for early breast cancer, regardless of estrogen-receptor status, tumor grade, or patient age.
Adding the anthracycline epirubicin to cyclophosphamide, methotrexate, and fluorouracil (CMF) is superior to CMF alone as adjuvant therapy for early breast cancer, regardless of estrogen-receptor status, tumor grade, or patient age.
The conclusion comes from two trials-The National Epirubicin Adjuvant Trial and the BR9601 trial-involving a total of 2,391 women with early breast cancer. After a median follow-up of 48 months, 2-year and 5-year relapse-free survival rates and 2-year and 5-year overall survival rates were significantly higher in the epirubicin group than in the CMF-alone group (91% vs. 85%; 76% vs. 69%; 95% vs. 92%; 82% vs. 75%, respectively; P<0.001). In addition, hazard ratios for relapse (or death without relapse) (0.69) and for death from any cause (0.67) were significant (P<0.001 for both).
While significantly more adverse effects occurred in the epirubicin group than in the CMF-alone group, they did not affect delivered dose intensity or quality of life.
Emerging multiplex UTI testing drives Medicare costs amid increased utilization
November 27th 2024A recent study found a sharp rise in Medicare claims for multiplex urinary tract infection testing from 2016 to 2023, underscoring a significant financial impact and the need for further research into its clinical benefits.
Read More
Reduced subsequent births reported after severe maternal morbidity
November 26th 2024Women experiencing severe maternal morbidity during their first pregnancy face significantly lower odds of subsequent births, emphasizing the need for personalized reproductive counseling and ongoing monitoring.
Read More
Maternal sFLT1 and EDN1 linked to late-onset preeclampsia
November 25th 2024A new study highlights the association of maternal soluble Fms-like tyrosine kinase 1 and endothelin 1 with preeclampsia severity, offering insights into the pathogenesis of early- and late-onset forms of the condition.
Read More
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
